Status:
COMPLETED
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
Lead Sponsor:
Ipsen
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-w...
Eligibility Criteria
Inclusion
- Participants who are able to comply with the protocol
- Participants with serum IGF-1 level above the ULN for age and sex, and serum fasting GH level above 2.5 μg/L
- Participants with acromegaly who are naïve to LAN treatment and about to initiate LAN
Exclusion
- Participants who are currently participating in any investigational study or clinical trial of acromegaly
- Pregnant participants
- Participants with hypersensitivity to somatostatin or related peptides or to any of the excipients
Key Trial Info
Start Date :
June 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2024
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT05431803
Start Date
June 30 2022
End Date
December 13 2024
Last Update
January 31 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital (PUMCH)
Beijing, China, 100000
2
Peking University Third Hospital (PUH3)
Beijing, China, 100000
3
Xiangya Hospital Central South University (XYHCSU)
Changsha, China, 410000
4
West China Hospital，Sichuan University (WCH)
Chengdu, China, 610000